The Oxysterols Receptor LXR Beta pipeline drugs market research report outlays comprehensive information on the Oxysterols Receptor LXR Beta targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Oxysterols Receptor LXR Beta pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Gastrointestinal, Oncology, Central Nervous System, and Metabolic Disorders which include the indications Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Breast Cancer, Melanoma, Alzheimer’s Disease, and Type 2 Diabetes. It also reviews key players involved in Oxysterols Receptor LXR Beta targeted therapeutics development with respective active and dormant or discontinued products.
The Oxysterols Receptor LXR Beta pipeline targets constitutes close to seven molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Preclinical, and Discovery stages are 5, and 1 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Oxysterols Receptor LXR Beta overview
Oxysterols Receptor LXR Beta is also known as Liver X Receptor Beta. This is a receptor that in humans is encoded by a gene LXRB. It is a nuclear receptor that belongs to the larger family of nuclear hormone receptors. This receptor is widely expressed in different tissues including liver, kidney, intestine, adipose tissue, and macrophages. These receptors act as transcription factors, regulating the expression of target genes in response to specific ligands. LXR Beta is activated by oxysterols, which are oxidized derivatives of cholesterol. LXR Beta plays a central role in the regulation of cholesterol metabolism. When oxysterols bind to LXR Beta, it induces the transcription of genes involved in cholesterol efflux, transport, and metabolism. This includes genes encoding proteins involved in reverse cholesterol transport, a process by which excess cholesterol is removed from peripheral tissues and transported back to the liver for excretion. LXR Beta activation has been associated with anti-inflammatory effects and involved in the regulation of various metabolic pathways, including fatty acid metabolism and glucose homeostasis.
For a complete picture of Oxysterols Receptor LXR Beta’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
